Despite being behind the curve for adoption of immunotherapy, the field of multiple myeloma has witnessed monumental advances in patient survival with the use of novel agents, according to a speaker at Chemotherapy Foundation Symposium.
The need for novel immunotherapies is becoming more urgent for patients with multiple myeloma because of the significant progress in treating the disease, Faith E. Davies, MBBCh, MRCP, MD, FRCPath, director of the myeloma clinical program and Center for Blood Cancers at Perlmutter Cancer Center and professor at NYU Grossman School of Medicine, told the
